The role of hypothalamic Pituitary-Adrenal axis dysfunction in the etiology of depressive disorders

Drugs of Today

Volumn 45, Issue 2, 2009, Pages 127-133

  Mclsaoc, Sean A ^a   Young, Allan H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; ANTALARMIN; ASTRESSIN; BUSPIRONE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CP 316311; DEXAMETHASONE; FLUOXETINE; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; ORG 34850; PRASTERONE; SEROTONIN; SEROTONIN 1A RECEPTOR; STRESS HORMONE; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DEPRESSION; DEPRESSION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NONHUMAN; SUICIDAL BEHAVIOR; TREATMENT RESPONSE;

DEPRESSIVE DISORDER; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 66249086541     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.2.1336104     Document Type: Article

References (52)

1. Board, F., Wadeson, R., Persky, H. Depressive affect and endocrine functions: Blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. AMA Arch Neurol Psychiatry 1957, 78(6): 612-20.
2. Nelson, J.C., Davis, J.M. DST studies in psychotic depression: A meta-analysis. Am J Psychiatry 1997,154(11): 1497-503.
3. Young, A.H., Gallagher, P., Porter, R.J. Elevation ofthecorti-sol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry 2002, 159(7): 1237-9.
4. Watson, S., Gallagher, P., Ritchie, J.C., Ferrier, I.N., Young, A.H. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004, 184: 496-502.
5. Cowen, P.J. Cortisol, serotonin and depression: All stressed out? Br J Psychiatry 2002,180: 99-100.
6. Wolkowitz, O.M., Reus, V.I. et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999,156(4): 646-9.
7. Bao, A.M., Meynen, G., Swaab, D.F. The stress system in depression and neurodegeneration: Focus on the human hypothalamus. Brain Res Rev 2008, 57(2): 531-53.
8. Krishnan, K.R., Doraiswamy, P.M., Lurie, S.N. et al. Pituitary size in depression. J Clin Endocrinol Metab 1991,72(2): 256-9.
9. Nemeroff, C.B., Krishnan, K.R., Reed, D., Leder, R., Beam, C, Dunnick, N.R. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 1992, 49(5): 384-7.
10. Young, A.H. Glucocorticoids, serotonin and mood. Br J Psychiatry 1994,165(2): 271-2.
11. Dinan, T.G., Scott, L.V. Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 2005, 207(3): 259-64.
12. van Rossum, E.F., Binder, E.B., Majer, M. et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006, 59(8): 681-8.
13. Webster, M.J., Knable, M.B., O'Grady, J., Orthmann, J., Weickert, C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002, 7(9): 985-94.
14. Bradley, R.G., Binder, E.B., Epstein, M.P. et al. Influence of child abuse on adult depression: Moderation by the corti-cotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008, 65(2): 190-200.
15. Watson, S., Owen, B.M., Gallagher, P., Hearn, A.J., Young, A.H., Ferrier, I.N. Family history, early adversity and the hypo-thalamic-pituitary-adrenal (HPA) axis: Mediation of the vulnerability to mood disorders. Neuropsychiatric Disease and Treatment 2007, 3(5): 647-53.
16. Zhou, D.F., Shen, Y.C., Shu, L.N., Lo, H.C. Dexamethasone suppression test and urinary MHPC X 504 determination in depressive disorders. Biol Psychiatry 1987, 22(7): 883-91.
17. Kunugi, H., Ida, I., Owashi,T. et al. Assessment of thedexam-ethasone/CRH test as a state-dependent marker for hypo-thalamic- pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study. Neuropsy-chopharmacology 2006,31(1): 212-20.
18. Zobel, A.W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., Ising, M. Cortisol response in the combined dexametha-sone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001, 35(2): 83-94.
19. Hook, J.N., Giordani, B., Schteingart, D.E. et al. Patterns of cognitive change over time and relationship to age following successful treatment of cushing's disease. J Int Neuropsychol Soc 2007,13(1): 21-9.
20. Starkman, M.N., Schteingart, D.E., Schork, M.A. Depressed mood and other psychiatric manifestations of Cushing's syndrome: Relationship to hormone levels. Psychosom Med 1981,43(1): 3-18.
21. Lupien, S.J., McEwen, B.S. The acute effects of corticosteroids on cognition: Integration of animal and human model studies. Brain Res Brain Res Rev 1997,24(1): 1-27.
22. Sapolsky, R.M., Krey, L.C., McEwen, B.S. The neuroen-docrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev 1986,7(3): 284-301.
23. Young, A.H., Sahakian, B.J., Robbins, T.W., Cowen, P.J. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychophar-macology 1999,145(3): 260-6.
24. Thompson, J.M., Gallagher, P., Hughes, J.H. et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005,186: 32-40.
25. Cavanagh, J.T., Van Beck, M., Muir, W., Blackwood, D.H. Case-control study of neurocognitive function in euthymic patients with bipolar disorder: An association with mania. Br J Psychiatry 2002,180: 320-6.
26. Lester, D. The dexamethasone suppression test as an indicator of suicide: A meta-analysis. Pharmacopsychiatry 1992, 25(6): 265-70.
27. Coryell, W., Young, E., Carroll, B. Hyperactivity of the hypo-thalamic-pituitary-adrenal axis and mortality in major depressive disorder. Psychiatry Res 2006,142(1): 99-104.
28. Westrin, A., Nimeus, A. The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters. Eur Psychiatry 2003,18(4): 166-71.
29. Arato, M., Banki, C.M., Bissette, G., Nemeroff, C.B. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989, 25(3): 355-9.
30. Raadsheer, F.C., van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J., Swaab, D.F. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 1995, 152(9): 1372-6.
31. Nemeroff, C.B., Owens, M.J., Bissette, G., Andorn, A.C., Stanley, M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988, 45(6): 577-9.
32. Dorovini-Zis, K., Zis, A.P. Increased adrenal weight in victims of violent suicide. Am J Psychiatry 1987,144(9): 1214-5.
33. Porter, R.J., Gallagher, P., Watson, S., Young, A.H. Cortico-steroid- serotonin interactions in depression: A review of the human evidence. Psychopharmacology 2004,173(1-2): 1-17.
34. Harmer, C.J., Bhagwagar, Z., Shelley, N., Cowen, P.J. Contrasting effects of citalopram and reboxetine on waking salivary Cortisol. Psychopharmacology 2003,167(1): 112-4.
35. Dinan, T.G. Serotonin and the regulation of hypothalamic-pituitary- adrenal axis function. Life Sci 1996, 58(20): 1683-94.
36. Man, M.S., Young, A.H., McAllister-Williams, R.H. Corticosterone modulation of somatodendritic 5-HTIA receptor function in mice. J Psychopharmacol 2002,16(3): 245-52.
37. Young, A.H., Sharpley, A.L, Campling, G.M., Hockney, R.A., Cowen, P.J. Effects of hydrocortisone on brain 5-HT function and sleep. J Affect Disord 1994, 32(2): 139-46.
38. Gartside, S.E., Leitch, M.M., Young, A.H. Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: Implications for the treatment of depression. Neuropsychopharmacology 2003, 28(9): 1572-8.
39. Johnson, D.A., Grant, E.J., Ingram, C.D., Gartside, S.E. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol Psychiatry 2007, 62(11): 1228-35.
40. Young, E.A., Altemus, M., Lopez, J.F. et al. HPA axis activation in major depression and response to fluoxetine: A pilot study. Psychoneuroendocrinology 2004, 29(9): 1198-204.
41. Mendelson, S.D., McEwen, B.S. Quantitative autoradiographic analyses of the time course and reversibility ofcorti-costerone-induced decreases in binding at 5-HTIA receptors in rat forebrain. Neuroendocrinology 1992, 56(6): 881-8.
42. Schmidt, P.J., Daly, R.C., Bloch, M. et al. Dehydro-epiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005,62(2): 154-62.
43. Belanoff, J.K., Rothschild, A.J., Cassidy, F. et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002, 52(5): 386-92.
44. Young, A.H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B.M., Ferrier, I.N. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004, 29(8): 1538-45.
45. DeBattista, C., Belanoff, J., Glass, S. et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006, 60(12): 1343-9.
46. Arana, G.W., Santos, A.B., Laraia, MX et al. Dexamethasone for the treatment of depression: A randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995, 152(2): 265-7.
47. Broadbear, J.H., Winger, G., Rivier, J.E., Rice, K.C., Woods, J.H. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: Differing profiles of activity in rhesus monkeys. Neuropsychopharmacology 2004, 29(6): 1112-21.
48. French, J.A., Fite, J.E., Jensen, H. et al. Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). Am J Primatol 2007, 69: 877-89.
49. Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., Stiger, T. A 6-week randomized, placebo-controlled trial of CP-316,3V (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165: 617-20.
50. Ravaris, C.L., Sateia, M.J., Beroza, K.W., Noordsy, D.L., Brinck-Johnsen, T. Effect of ketoconazole on a hypophysec-tomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 1988, 45(10): 966-7.
51. Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., Wiedemann, K. Metyrapone as additive treatment in major depression: A double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004, 61(12): 1235-44.
52. Gallagher, P., Malik, N., Newham, J., Young, A., Ferrier, I., Mackin, P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008, 23(1): CD005168.